pharmaphorum

DECEMBER 14, 2022

The two partners have revealed the first clinical data from a phase 2b trial of a personalised vaccine consisting of 34 mRNAs, each targeting mutations – identified by gene sequencing – that are thought to be driving a patient’s cancer. Access to sequencing could, however, be a major obstacle at the population level.

Vaccine 98

Vaccine Vaccination Trials Gene Sequencing 98

pharmaphorum

JANUARY 5, 2023

However, its messenger RNA (mRNA) platform – building on continuous advances in basic and applied mRNA science – permits the development of therapeutics and vaccines for other infectious diseases, immune-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases as well.

Gene Sequencing 97

Gene Sequencing DNA Vaccine Vaccination 97

pharmaphorum

OCTOBER 12, 2022

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. The deal focuses on mRNA-4157 – also known as V940 – which targets up to 34 unique tumour-associated antigens or neoantigens that are expressed by a patient’s cancer cells.

Vaccine 105

Vaccine Vaccination Gene Sequencing RNA 105